Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more
Kwangdong Phar (009290) - Net Assets
Latest net assets as of September 2025: ₩632.20 Billion KRW
Based on the latest financial reports, Kwangdong Phar (009290) has net assets worth ₩632.20 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.22 Trillion) and total liabilities (₩589.90 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩632.20 Billion |
| % of Total Assets | 51.73% |
| Annual Growth Rate | 7.23% |
| 5-Year Change | 23.12% |
| 10-Year Change | 63.68% |
| Growth Volatility | 4.41 |
Kwangdong Phar - Net Assets Trend (2011–2024)
This chart illustrates how Kwangdong Phar's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kwangdong Phar (2011–2024)
The table below shows the annual net assets of Kwangdong Phar from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩618.27 Billion | +5.14% |
| 2023-12-31 | ₩588.05 Billion | +7.49% |
| 2022-12-31 | ₩547.05 Billion | +3.76% |
| 2021-12-31 | ₩527.24 Billion | +4.99% |
| 2020-12-31 | ₩502.18 Billion | +12.23% |
| 2019-12-31 | ₩447.46 Billion | +3.86% |
| 2018-12-31 | ₩430.84 Billion | +3.49% |
| 2017-12-31 | ₩416.30 Billion | +4.16% |
| 2016-12-31 | ₩399.68 Billion | +5.81% |
| 2015-12-31 | ₩377.73 Billion | +20.14% |
| 2014-12-31 | ₩314.40 Billion | +8.11% |
| 2013-12-31 | ₩290.82 Billion | +8.81% |
| 2012-12-31 | ₩267.27 Billion | +7.11% |
| 2011-12-31 | ₩249.52 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kwangdong Phar's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 52090684264000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩520.91 Billion | 89.95% |
| Other Components | ₩58.22 Billion | 10.05% |
| Total Equity | ₩579.12 Billion | 100.00% |
Kwangdong Phar Competitors by Market Cap
The table below lists competitors of Kwangdong Phar ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Provident Bancorp Inc
NASDAQ:PVBC
|
$195.90 Million |
|
GD Culture Group Limited
NASDAQ:GDC
|
$195.90 Million |
|
Atria Oyj A
HE:ATRAV
|
$195.99 Million |
|
North East Rubbers Public Company Limited
BK:NER
|
$196.00 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
$195.75 Million |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
$195.73 Million |
|
Cloud Live Technology Group Co Ltd
SHE:002306
|
$195.55 Million |
|
Prabha Energy Limited
NSE:PRABHA
|
$195.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kwangdong Phar's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 544,616,130,050 to 579,122,160,860, a change of 34,506,030,810 (6.3%).
- Net income of 40,480,912,830 contributed positively to equity growth.
- Dividend payments of 4,007,878,200 reduced retained earnings.
- Share repurchases of 4,067,425,350 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩40.48 Billion | +6.99% |
| Dividends Paid | ₩4.01 Billion | -0.69% |
| Share Repurchases | ₩4.07 Billion | -0.7% |
| Other Changes | ₩2.10 Billion | +0.36% |
| Total Change | ₩- | 6.34% |
Book Value vs Market Value Analysis
This analysis compares Kwangdong Phar's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.62x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.94x to 0.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩9657.06 | ₩9070.00 | x |
| 2018-12-31 | ₩10087.45 | ₩9070.00 | x |
| 2019-12-31 | ₩10686.08 | ₩9070.00 | x |
| 2020-12-31 | ₩11627.42 | ₩9070.00 | x |
| 2021-12-31 | ₩12151.16 | ₩9070.00 | x |
| 2022-12-31 | ₩12593.06 | ₩9070.00 | x |
| 2023-12-31 | ₩13588.02 | ₩9070.00 | x |
| 2024-12-31 | ₩14719.33 | ₩9070.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kwangdong Phar utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.99%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.47%
- • Asset Turnover: 1.40x
- • Equity Multiplier: 2.02x
- Recent ROE (6.99%) is below the historical average (7.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 12.06% | 9.53% | 0.98x | 1.30x | ₩5.11 Billion |
| 2012 | 10.46% | 8.36% | 0.85x | 1.46x | ₩1.22 Billion |
| 2013 | 7.62% | 4.70% | 1.10x | 1.47x | ₩-6.89 Billion |
| 2014 | 11.20% | 6.71% | 1.18x | 1.41x | ₩3.76 Billion |
| 2015 | 10.01% | 3.66% | 1.44x | 1.90x | ₩20.64 Million |
| 2016 | 7.52% | 2.66% | 1.55x | 1.82x | ₩-9.24 Billion |
| 2017 | 5.92% | 2.03% | 1.58x | 1.84x | ₩-15.99 Billion |
| 2018 | 5.51% | 1.89% | 1.61x | 1.81x | ₩-18.19 Billion |
| 2019 | 5.45% | 1.86% | 1.56x | 1.87x | ₩-19.24 Billion |
| 2020 | 9.50% | 3.65% | 1.50x | 1.74x | ₩-2.40 Billion |
| 2021 | 4.81% | 1.79% | 1.51x | 1.77x | ₩-25.90 Billion |
| 2022 | 4.67% | 1.69% | 1.54x | 1.80x | ₩-27.56 Billion |
| 2023 | 6.79% | 2.44% | 1.40x | 1.98x | ₩-17.50 Billion |
| 2024 | 6.99% | 2.47% | 1.40x | 2.02x | ₩-17.43 Billion |
Industry Comparison
This section compares Kwangdong Phar's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $383,167,334,826
- Average return on equity (ROE) among peers: 4.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kwangdong Phar (009290) | ₩632.20 Billion | 12.06% | 0.93x | $195.84 Million |
| Daehan Flour Mills Co Ltd (001130) | $489.63 Billion | 6.13% | 0.50x | $92.10 Million |
| Daesang Corp (001680) | $484.66 Billion | 6.60% | 1.67x | $297.74 Million |
| Daesang Corp Preference Shares (001685) | $867.27 Billion | 7.45% | 1.66x | $257.13 Million |
| Korea Ind (002140) | $66.54 Billion | 7.12% | 1.23x | $24.66 Million |
| Choheung (002600) | $149.64 Billion | 0.24% | 1.63x | $16.50 Million |
| Sam Yang Foods (003230) | $53.38 Billion | 0.00% | 4.82x | $2.87 Billion |
| Daejoo Inc (003310) | $47.00 Billion | 3.26% | 0.70x | $60.49 Million |
| Harim Holdings Co. Ltd (003380) | $808.31 Billion | 21.63% | 7.74x | $434.99 Million |
| Hansung Ent (003680) | $52.28 Billion | 2.70% | 3.49x | $11.05 Million |
| Namyang Dairy (003920) | $812.96 Billion | -7.24% | 0.15x | $115.08 Million |